-
Novartis drastic change: Establishing a chief strategy and growth officer, restructuring will affect thousands of employees
Time of Update: 2022-05-29
Novartis' global chief executive Vas Narasimhan expects to cut sales and administrative expenses by at least $1 billion a year through 2024 .
5 billion, an increase of 5% year-on-year, of which the sales of the innovative medicine business unit (IM) were approximately US$10.
-
Two more senior executives of multinational pharmaceutical companies may switch to local companies
Time of Update: 2021-12-29
Eid, an expert in the medical field, officially announced that he had joined Hengrui Pharmaceuticals as executive vice president, chief medical officer and head of global drug development.
-
Tianjing Biotech further strengthens the executive team and announces new chief financial officer and chief strategy officer
Time of Update: 2021-11-14
Shanghai, China and Gaithersburg, USA, November 1, 2021/PRNewswire/ - Tianjing Bio ("Company") (NASDAQ: IMAB) is a company that is moving from the clinical stage to commercialization Biopharmaceutical companies are committed to target biological research of innovative biological drugs, antibody technology, clinical development and product commercialization in China and the United States, and provide new and effective treatment methods for the urgently needed cancer treatment fields around the world .
-
Many senior executives of pharmaceutical companies quit or set off a battle for high-end professionals in the industry
Time of Update: 2020-02-21
[industry news of pharmaceutical network] recently, Ruikang pharmaceutical announced that the board of directors received the written resignation report of Ms Quan Yuhua, the independent director of t
-
The situation of new soybean sellers in South America is more stable
Time of Update: 2001-04-03
OA show ('918 '); [the situation of new soybean sellers in South America is more stable] the situation of new grain sellers in South America is more stable Brazil's harvest is nearly 50% complete In s
